Hypothesis testing: Is clozapine's superior efficacy dependent on moderate D2 receptor occupancy?

Biological Psychiatry

Volumn 43, Issue 2, 1998, Pages 79-83

  Carpenter Jr , William T ^a,c   Zito, Julie Magno ^a   Vitrai, Joszef ^b   Volavka, Jan ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Clozapine; Drug treatment; Hypothesis testing; Receptor occupancy; Schizophrenia

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR;

ARTICLE; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG RECEPTOR BINDING; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RATING SCALE; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; TREATMENT OUTCOME;

EID: 0032518569     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00226-1     Document Type: Article

References (38)

1. American Psychiatric Association (1987): Diagnostic and Statistical Manual of Mental Disorders, 3rd ed rev. Washington, DC: American Psychiatric Press
2. 3-like receptor supersensitivity and dopamine receptor subsensitivity in the rat medial prefrontal cortex after intraventricular administration of the neurotoxin 5, 7-hydroxytryptamine: A micro-iontophoretic study. Neuroscience.
3. 2 receptor blocking agent. Curr Therapeutic Res 40:492-499.
4. Breier A (1994a): Clozapine and noradrenergic function: Support for a novel hypothesis for superior efficacy. J Clin Psychiatry 55(suppl B): 122-125.
5. Breier A (1994b): The effect of clozapine on plasma norepinephrine: Relationship to clinical efficacy. Neuropsychopharmacology 10:1-7.
6. Bymaster FP, Calligaro DO, Falcone JF, et al (1995): Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96.
7. Carpenter WT (1995): Serotonin-dopamine antagonists and treatment of negative symptoms. J Clin Psychopharmacol 15(suppl 1):30S-35S.
8. Carpenter WT, Conley RR, Buchanan RW, Breier A, Tamminga CA (1995): Patient response and resource management: Another view of clozapine treatment of schizophrenia. Am J Psychiatry 152:827-832.
9. Chouinard G, Jones BD, Remington G, et al (1993): A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25-40.
10. Cohen J (1987): Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Lawrence Erlbaum Associates.
11. Creese I, Snyder SH (1976): Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481-483.
12. Davis JM, Erikson S, Dekirmenjian H (1978): Plasma levels of antipsychotic drugs and clinical response. In: Lipton MA, DiMascio A, Killam KF, editors. Psychopharmacology. A Generation of Progress. New York: Raven Press, pp 905-915.
13. 2/1C antagonist, and negative symptoms in schizophrenia: A placebo-controlled double-blind trial. Br J Psychiatry 163:451-455.
14. 2 dopamine receptor occupancy with schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71-76.
15. 2-receptor occupancy in clozapine treated patients. J Clin Psychiatry 55(suppl B):67-69.
16. Kane J, Honigfeld G, Singer J, Meltzer H, The Clozaril Collaborative Study Group (1988): Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45:789-796.
17. Levinson DF, Simpson GM, Lo ES, et al (1995): Fluphenazine plasma levels, dosage, efficacy, and side effects. Am J Psychiatry 152:765-771.
18. 2 receptors. Psychopharmacology 112:S40-S54.
19. Marder SR, Meibach RC (1994): Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-835.
20. Meltzer HY (1992): The importance of serotonin-dopamine interactions in the action of clozapine. Br J Psychiatry 160(suppl 17):22-29.
21. Meltzer HY (1994): An overview of the mechanism of clozapine. J Clin Psychiatry 55(suppl B):47-52.
22. Meltzer HY, Gudelsky GA (1992): Dopaminergic and serotonergic effects of clozapine: Implications for a unique clinical profile. Arzneimittelforschung 42:268-272.
23. Meltzer HY, Nash JF (1991): Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 42:587-604.
24. Moghaddam B, Bunney BS (1990): Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: An in vivo microdialysis study. J Neurochem 54:1755-1760.
25. Muller-Spahn F, The International Risperidone Research Group (1992): Risperidone in the treatment of chronic schizophrenic patients. An international double-blind parallel-group study versus haloperidol. Clin Neuropharmacol 15(suppl 1):90A-91A.
26. Overall JE, Gorham DR (1962): Brief Psychiatric Rating Scale. Psychol Rep 10:799-812.
27. 2 receptor blocker. Drug Dev Res 8:205-211.
28. 4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology 120:365-368.
29. 4. Neuropsychopharmacology 7:261-284.
30. Seeman P, Lee T, Chau-Wong M, Wong K (1976): Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717-719.
31. Stern RG, Kahn RS, Davidson M, Nora RM, Davis KL (1994): Early response to clozapine in schizophrenia. Am J Psychiatry 151:1817-1818.
32. Svensson TH, Tung CS, Grenhoff J (1989): The 5-HT antagonist ritanserin blocks the effect of prefrontal cortex inactivation on rat A10 dopamine neurons in vivo. Acta Physiol Scand 136:497-498.
33. Tamminga CA, Dannals RF, Frost JJ, Wong DF, Wagner HN (1993): Neuroreceptor and neurochemistry studies with positron-emission tomography in psychiatric illness: Promise and progress. In: Oldham JM, Riba MB, Tasman A, editors. Review of Psychiatry, vol 12. Washington, DC: American Psychiatric Press, pp 481-510.
34. 3-like receptors in the action of clozapine. J Clin Psychiatry 55(suppl B):23-26.
35. Wiesel FA, Nordstrom AL, Farde L, Eriksson B (1994): An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology 14:31-38.
36. Wistedt B, Jorgensen A, Wiles D (1982): A depot neuroleptic withdrawal study: Plasma concentration of fluphenazine and flupenthixol and relapse frequency. Psychopharmacology 78:301-304.
37. Youngren KD, Moghaddam B, Bunney BS, Roth RH (1994): Preferential activation of dopamine overflow in prefrontal cortex produced by chronic clozapine treatment. Neurosci Lett 165:41-44.
38. Zito JM, Volavka J, Craig TJ, Czobor P, Banks S, Vitrai J (1993): Pharmacoepidemiology of clozapine in 202 inpatients with schizophrenia. Ann Pharmacother 27:1262-1269.